Curaleaf Holdings (CURA) AI Stock Analysis

• Market Cap: $863.38M
• Dividend Yield: N/A
• Average Volume (3M): 224.89K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.66
• Revenue Growth: -0.11%
• EPS Growth: 11.22%
• Country: CA
• Employees: 5,519
• Sector: Healthcare
• Sector Strength: 46
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -0.10
• Shares Outstanding: 663,381,650
• 10 Day Avg. Volume: 216,940
• 30 Day Avg. Volume: 224,890
• PEG Ratio: N/A
• Price to Book (P/B): 0.75
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 9.76
• Enterprise Value/Market Cap: 1.55
• Enterprise Value/Revenue: 0.25
• Enterprise Value/Gross Profit: 2.24
• Enterprise Value/Ebitda: 1.41
• 1Y Price Target: $5.26
• Price Target Upside: 361.07% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 54 Neutral
• Price Target: C$1.00 ▼(-12.28%Downside)

Curaleaf Holdings' overall stock score reflects significant financial challenges, including declining revenues and persistent net losses, countered by strong international growth and improved margins. Technical indicators suggest a bearish trend, while valuation metrics reflect ongoing profitability issues. Strategic expansions and operational efficiency improvements provide some optimism for future growth.

Positive Factors

Market Expansion

Expansion into new markets is anticipated to increase revenue streams.

Operational Efficiency

Operational efficiencies are expected to drive margins.

Sales Growth

Sales growth in 2Q24 was largely driven by wholesale revenue growth as the international segment continues to gain traction.

Negative Factors

Competition

The company is facing stiff competition in the cannabis industry.

Financial Performance

EBITDA margins fell short of expectations due to higher G&A spend and heavy promotions at the start of the quarter.

Regulatory Challenges

There are concerns about regulatory challenges in the cannabis market.

Curaleaf Holdings Business Overview & Revenue Model

Company Description

Curaleaf Holdings, Inc. operates a cannabis operator in the United States. It operates through Domestic Operations and International Operations segments. The company engages in the cultivation, production, and sale of cannabis products through retail and wholesale channels. In addition, it offers flowers, pre-rolls, flower pods, and dry-herb vaporizer cartridges; concentrates for vaporizing, such as pre-filled vaporizer cartridges and disposable vaporizer pens; and concentrates for dabbing, including distillate droppers, mints, topical balms and lotions, tinctures, lozenges, capsules, and edibles. Further, the company provides hemp-based CBD and cannabigerol products. The company was founded in 2010 and is headquartered in New York, New York.

How the Company Makes Money

Curaleaf Holdings generates revenue primarily through the sale of cannabis products across its retail dispensaries and wholesale channels. The company's key revenue streams include the direct sale of proprietary branded products, such as Curaleaf, Select, and Grassroots, which are available in various forms including flower, pre-rolls, oils, and edibles. Additionally, Curaleaf earns revenue through wholesale operations where it supplies cannabis products to other dispensaries and retailers. Strategic partnerships and acquisitions also play a vital role in expanding Curaleaf's market presence and product offerings, contributing to its earnings. The company's vertically integrated model ensures control over the entire supply chain, from cultivation to distribution, optimizing cost efficiencies and product quality.

Curaleaf Holdings Financial Statement Overview

Summary

Curaleaf Holdings faces challenges with profitability, evidenced by declining revenues and persistent net losses. While cash flow and operational efficiency show some improvement, high debt levels and leverage risks pose financial stability concerns. The company needs to enhance profitability and manage leverage for sustainable growth.

Income Statement

The company shows a declining revenue trend with a slight drop in total revenue from $1.34 billion in the previous year to $1.31 billion in TTM. The gross profit margin has decreased, indicating increased cost pressures. Furthermore, negative net income results in a negative net profit margin, highlighting ongoing profitability challenges. Though EBIT and EBITDA margins show slight improvements, they remain low, impacting overall profitability.

Balance Sheet

The balance sheet shows a relatively high debt-to-equity ratio, which poses leverage risks. However, the equity ratio remains stable, suggesting a moderate level of equity financing. Return on equity is negative due to net losses, impacting shareholder returns. Overall, the balance sheet shows stability but with notable leverage risks.

Cash Flow

Operating cash flow remains positive, reflecting operational viability. The free cash flow has grown compared to previous periods, improving cash flow stability. However, the free cash flow to net income ratio is affected by persistent losses, and the operating cash flow to net income ratio indicates inefficiencies. Overall, cash flow management shows improvements but remains constrained by net income losses.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.31B	1.34B	1.35B	1.34B	1.21B	626.64M
Gross Profit	596.92M	639.25M	614.45M	579.03M	687.59M	390.51M
EBITDA	217.71M	233.14M	238.76M	220.97M	278.98M	128.59M
Net Income	-228.21M	-215.42M	-281.20M	-376.93M	-109.13M	-61.33M
Balance Sheet
Total Assets	2.95B	2.95B	3.10B	3.40B	3.26B	2.39B
Cash, Cash Equivalents and Short-Term Investments	121.87M	93.03M	91.82M	163.18M	299.33M	73.54M
Total Debt	846.60M	853.82M	883.55M	931.91M	753.65M	577.71M
Total Liabilities	1.98B	1.96B	1.93B	2.00B	1.45B	1.01B
Stockholders Equity	814.02M	861.21M	1.05B	1.28B	1.76B	1.38B
Cash Flow
Free Cash Flow	62.65M	64.42M	5.05M	-91.96M	-205.92M	-113.92M
Operating Cash Flow	159.03M	162.57M	75.26M	46.40M	-33.96M	12.36M
Investing Cash Flow	-93.78M	-93.83M	-78.69M	-228.62M	-163.97M	-197.11M
Financing Cash Flow	-48.01M	-54.24M	-67.02M	50.54M	424.80M	224.08M

Curaleaf Holdings Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 1.14
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:CURA, the sentiment is Neutral. The current price of 1.14 is below the 20-day moving average (MA) of 1.14, below the 50-day MA of 1.20, and below the 200-day MA of 2.25, indicating a bearish trend. The MACD of -0.03 indicates Positive momentum. The RSI at 48.38 is Neutral, neither overbought nor oversold. The STOCH value of 47.66 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for TSE:CURA.

Curaleaf Holdings Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CURA	54 Neutral	$863.38M	―	-25.08%	―	-0.11%	11.22%
Sector *	51 Neutral	$7.41B	0.32	-61.11%	2.34%	16.99%	1.69%
CGC		$254.47M	―	-122.10%	―	―	―
ACB		$220.72M	82.70	3.05%	―	―	―
CRON		$731.91M	14.96	4.61%	―	―	―
TCNNF		$693.49M	―	-12.39%	―	―	―
CRLBF		$231.04M	―	-17.34%	―	―	―

Curaleaf Holdings Corporate Events

Curaleaf Strengthens Leadership with New President and Key Executive Hires

Curaleaf Holdings has appointed Rahul Pinto as the new President to lead its global commercial functions, alongside strengthening its leadership team with three new Senior Vice Presidents in digital, retail merchandising, and brand marketing. This strategic move aims to enhance Curaleaf’s position as a global leader in the cannabis industry by leveraging Pinto’s extensive experience in consumer packaged goods and retail, as well as the expertise of the new hires, to drive innovation and growth.

The most recent analyst rating on (TSE:CURA) stock is a Buy with a C$6.50 price target. To see the full list of analyst forecasts on Curaleaf Holdings stock, see the TSE:CURA Stock Forecast page.

Curaleaf Holdings Confirms Board and Auditor at 2025 AGM

Curaleaf Holdings, Inc. recently held its 2025 Annual General Meeting of Shareholders, where key resolutions were passed, including the election of ten directors and the reappointment of PKF O’Connor Davies, LLP as the company’s auditor. The meeting, conducted via webcast, saw significant shareholder participation with over 1.7 billion votes cast. These decisions are expected to reinforce Curaleaf’s governance and operational strategies, potentially impacting its market positioning and stakeholder relations positively.

The most recent analyst rating on (TSE:CURA) stock is a Buy with a C$6.50 price target. To see the full list of analyst forecasts on Curaleaf Holdings stock, see the TSE:CURA Stock Forecast page.

Curaleaf Holdings Strengthens Governance at 2025 Annual Meeting

Curaleaf Holdings, Inc. held its 2025 Annual General Meeting of Shareholders via webcast, where key resolutions were passed, including the election of directors and the reappointment of the company’s auditor. The meeting saw a significant number of votes cast, reflecting strong shareholder engagement. These developments are expected to reinforce Curaleaf’s governance and operational stability, positively impacting its market positioning and stakeholder confidence.

The most recent analyst rating on (TSE:CURA) stock is a Buy with a C$6.50 price target. To see the full list of analyst forecasts on Curaleaf Holdings stock, see the TSE:CURA Stock Forecast page.

Curaleaf Holdings Reports Q1 2025 Results with Strong International Growth

Curaleaf Holdings reported a total revenue of $310 million for the first quarter of 2025, with a notable international revenue growth of 74% year-over-year. Despite a decrease in net revenue compared to the previous year, the company achieved a 50% adjusted gross margin and continued to expand its product offerings and retail locations, demonstrating resilience and strategic positioning for long-term success.

Curaleaf Holdings to Announce Q1 2025 Financial Results

Curaleaf Holdings announced it will release its first quarter 2025 financial and operational results on May 8, 2025, after market close. The company will host a conference call and webcast to discuss these results, providing stakeholders with insights into its performance and strategic direction. This announcement is significant as it offers an opportunity for investors and analysts to evaluate Curaleaf’s market positioning and operational effectiveness in the evolving cannabis industry.